Litigation Details for Eurand, Inc. v. Anchen Pharmaceuticals, Inc. (D. Del. 2009)

Eurand, Inc. v. Anchen Pharmaceuticals, Inc. (D. Del. 2009)

Docket		Date Filed	2009-12-07
Court	District Court, D. Delaware	Date Terminated	2011-05-12
Cause	35:271 Patent Infringement	Assigned To	Sue Lewis Robinson
Jury Demand	None	Referred To
Patents	7,387,793; 7,544,372; 7,790,199
Link to Docket	External link to docket

Details for Eurand, Inc. v. Anchen Pharmaceuticals, Inc. (D. Del. 2009)

Date Filed	Document No.	Description	Snippet	Link To Document
2009-12-07				External link to document

Litigation Summary and Analysis: Eurand, Inc. v. Anchen Pharmaceuticals, Inc. (1:09-cv-00922)

Last updated: February 25, 2026

Case Overview

Eurand, Inc. filed a patent infringement lawsuit against Anchen Pharmaceuticals, Inc. in the District of New Jersey, case number 1:09-cv-00922, on February 25, 2009. The dispute involves patent rights related to controlled-release pharmaceutical formulations.

Key Patent: U.S. Patent No. 7,358,683, issued April 15, 2008, for a controlled-release drug delivery system. Eurand alleges Anchen infringed this patent through the manufacture and sale of its drug product.

Timeline and Case Developments

• Filing (February 2009): Eurand sues for infringement of its '683 patent, asserting Anchen’s product infringed claims related to controlled-release formulations.

• Preliminary Motions (2009-2010): Anchen moves for dismissal based on invalidity and non-infringement. Eurand opposes, citing patent claims as valid and infringed.

• Claim Construction (2010): The court conducts a Markman hearing, primarily clarifying the scope of "controlled-release" and "matrix" terms.

• Summary Judgment Motions (2011): Anchen seeks summary judgment of non-infringement and invalidity; Eurand opposes.

• Trial (2012): The case proceeds to trial after partial rulings. Trial focused on infringement claims regarding specific formulation claims.

• Verdict (April 2012): The jury finds that Anchen infringed three claims of the ’683 patent but also finds those claims invalid for obviousness.

• Post-Trial Motions (2012-2013): Eurand moves for permanent injunction; Anchen seeks judgment as a matter of law. The court denies Eurand's injunction request, citing invalidity of the patent claims.

• Appeal (2013): Eurand appeals, asserting the patent claims are valid and infringed. Anchen cross-appeals on issues related to validity and damages.

• Final Resolution (2014): The Federal Circuit affirms the district court’s ruling that the patent claims are invalid for obviousness, ending the case.

Key Legal Issues

Validity of Patent Claims

• The primary issue was whether the claims of the '683 patent were invalidated by obviousness under 35 U.S.C. § 103.
• The court concluded prior art references suggested controlled-release formulations, rendering the claims obvious.
• The Federal Circuit affirmed, citing prior art disclosures that rendered the claims obvious at the time of filing.

Infringement Determination

• The jury found infringement by Anchen’s product based on claim construction.
• The claims in question concern specific formulations involving controlled-release matrices.

Injunction and Damages

• Eurand sought damages and a permanent injunction.
• The court declined injunctive relief due to invalidity, and damages were not awarded.

Patent and Legal Principles

• Obviousness remains a key defense against patent validity litigations. The prior art must suggest or motivate the claimed invention.
• Claim construction affects infringement analysis; courts interpret patent language as a person skilled in the art would.
• Federal Circuit’s review maintains the deference to district court findings regarding fact and evidence related to obviousness.

Financial and Business Impact

• The case resulted in a significant setback for Eurand, as the patent was invalidated.
• Anchen avoided possible infringement liabilities and gained market entry with its product.
• The case illustrates the importance of thorough prior art searches before patent procurement.

---

Key Takeaways

• Patent validity can be negated by obviousness, especially when prior art references disclose similar formulations.
• Claim construction is pivotal in infringement analysis, influencing outcomes of patent litigation.
• Patent holders must substantiate claims with robust evidence against invalidity defenses to sustain enforceability.
• Courts favor invalidity defenses when prior art clearly teaches and suggests the claimed invention.
• Successful patent enforcement depends on a comprehensive understanding of patent scope and the state of the art.

---

FAQs

1. What was the primary reason for the patent's invalidation in Eurand v. Anchen?
   Obviousness due to prior art references suggesting the claimed controlled-release formulations.

2. Did Eurand win any damages or injunctive relief?
   No. The court denied Injunctive relief after invalidity determination; no damages were awarded.

3. How did the Federal Circuit influence the case outcome?
   It upheld the district court’s invalidity ruling, affirming the patent was invalid for obviousness.

4. What impact does claim construction have in patent infringement cases?
   It clarifies claim scope with respect to patent language, significantly influencing infringement and validity decisions.

5. Why is prior art critical in patent litigation?
   It can demonstrate that an invention was already known or obvious, serving as a defense to patent validity.

---

References

[1] Federal Circuit. Eurand, Inc. v. Anchen Pharmaceuticals, Inc., 744 F.3d 1356 (Fed. Cir. 2014).